Skip to Content
  • Previous Rank
    19
  • Revenue 3 Yr Annual Growth Rate
    31%
  • Revenue 3 Yr Growth Rank
    39
  • EPS 3 Yr Annual Growth Rate
    273%
  • EPS 3 Yr Growth Rank
    1
  • Total Return 3 Yr Annual Rate
    47%
  • Total Return 3 Yr Rank
    15

This biotech licensor’s two hit drugs–Krypolis, used to treat blood cancer, and Promacta, used to prevent bleeding episodes–injected big royalties last year.

41319CFF-E47E-4BA5-B1B8-ECA4D480B0DFCreated with sketchtool.62900797-6A09-46DF-8323-A45758A81292Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Buy Now

Company Information

Location
San Diego, Calif.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak3
Years on List3
CEO
John Higgins
Websitehttp://www.ligand.com
Includes a $220 million income benefit relating to the company's deferred tax assets.!Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$87
Net Income Past Four Quarters ($M)$263

Growth Rates and Ranks

Revenue 3 Yr Growth Rank39
EPS 3 Yr Annual Growth Rate273%
EPS 3 Yr Growth Rank1
Total Return 3 Yr Annual Rate47%
Total Return 3 Yr Rank
15